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Abstract
Background: The systematic study of the human genome indicates that the inter-individual variability is greater than
expected and it is not only related to sequence polymorphisms but also to gene copy number variants (CNVs). Congenital
Adrenal Hyperplasia due to 21-hydroxylase deficiency (21OHD) is the most common autosomal recessive disorder with a
carrier frequency of 1:25 to 1:10. The gene that encodes 21-hydroxylase enzyme, CYP21A2, is considered to be one of the
most polymorphic human genes. Copy number variations, such as deletions, which are severe mutations common in
21OHD patients, or gene duplications, which have been reported as rare events, have also been described. The correct
characterization of 21OHD alleles is important for disease carrier detection and genetic counselling
Methodology and Findings: CYP21A2 genotyping by sequencing has been performed in a random sample of the Spanish
population, where 144 individuals recruited from university students and employees of the hospital were studied. The
frequency of CYP21A2 mutated alleles in our sample was 15.3% (77.3% were mild mutations, 9% were severe mutations and
13.6% were novel variants). Gene dosage assessment was also performed when CYP21A2 gene duplication was suspected.
This analysis showed that 7% of individuals bore a chromosome with a duplicated CYP21A2 gene, where one of the copies
was mutated.
Conclusions: As far as we know, the present study has shown the highest frequency of 21OHD carriers reported by a
genotyping analysis. In addition, a high frequency of alleles with CYP21A2 duplications, which could be misinterpreted as
21OHD alleles, was found. Moreover, a high frequency of novel genetic variations with an unknown effect on 21-
hydroxylase activity was also found. The high frequency of gene duplications, as well as novel variations, should be
considered since they have an important involvement in carrier testing and genetic counseling.
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Introduction
Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency
(21OHD) (OMIM +201910) is the most common autosomal
recessive disorder. This enzymatic deficiency impairs synthesis of
cortisol and/or aldosterone from cholesterol in the adrenal cortex.
The severe deficiency of steroid 21-hydroxylase enzyme (21OH; EC
1.14.99.10) results in the classic form of the disease, which is divided
firstly, into the salt-wasting form, where neither cortisol nor
aldosterone is synthesized; and secondly, into the simple virilizing
form, where a residual activity of 21OH allows aldosterone synthesis.
The moderate deficiency of 21OH results in the non classic form of
the disease (NC21OHD), which is characterized by precocious
pseudopuberty, acne, hirsutism and oligomenorrhea, although
phenotypical expression is highly variable [1–3].
The incidence of the classic form of the disease is 1:23000–
1:10000 depending on the populations studied [4–8] and the
incidence of the NC21OHD is 1:500–1:100 in most populations. It
can be more frequent in other populations like in the Ashkenazi
Jews with a 1:27 incidence [2,9]. The carrier frequency of
21OHD, estimated on the basis of newborn screening, is between
0.011 and 0.020 for severe mutations and 0.08 to 0.18 for mild
ones. On the other hand, genotyping analyses done in New
Zealanders and Middle Europeans have shown higher frequencies
for carriers of severe mutations (0.040–0.055) and lower for mild
ones (0.02–0.04) [4,10]. Most 21OHD patients are carriers of
deletions of the gene encoding 21OH, CYP21A2, or of any of the 9
most frequent point mutations derived from the non-functional
CYP21A1P pseudogene. The rest are due to rare genetic variants,
descriptions of which are continuously increasing [11–20].
The CYP21A2 gene is 98% homologous to the CYP21A1P
pseudogene in its coding sequence and 96% in introns. Both lie in
the Major Histocompatibility Complex at chromosome 6p21.3,
which is a complex organization of genes with variation in gene
copy number and size [1,21]. They constitute a genetic unit
together with neighboring genes RP1, C4, TNXB, and their
truncated pseudogenes RP2 and TNXA. This genetic unit is termed
RCCX module (RP-C4-CYP21-TNX) and constitutes a highly
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variable stretch of DNA of approximately 30 kb [22] (Figure 1).
Most chromosomes bear two of these modules, one with the
CYP21A1P pseudogene and the other with the CYP21A2 gene.
Monomodular and trimodular haplotypes have also been
described [22–27].
The high genetic variability at CYP21A2 locus makes the
characterization of 21OHD alleles difficult, and, hence, compli-
cates disease carrier detection and genetic counseling. In this
paper, an in-depth study of the CYP21A2 gene in a group of 144
individuals is described. We found an unexpectedly high 21OHD
carrier frequency, CYP21A2 gene duplications and CYP21A2 novel
genetic variations. The results of the current work should be
considered for 21OHD genetic diagnosis and counseling.
Results
Copy Number Variations: frequency of CYP21A2 gene
duplications
The CYP21A2 gene dosage assessment by Real-Time PCR and by
the specific amplification of each duplicated gene showed that 8 out
of the 144 individuals were carriers of CYP21A2 gene duplication
with one of the copies p.Gln318X mutated (UniProtKB ID P08686).
In all the cases, the mutation was in linkage disequilibrium with two
uncommon genetic variants, a G.A change in intron 2 at position -
79 and a C.T change at nucleotide 13 in the 39 UTR region (c.293-
79G.A and c.*13C.T, respectively, GenBank Ref. ID
NM000500.5). The PCRs for the amplification of the CYP21A2
duplicated genes confirmed the duplication. The specific sequencing
of each gene showed the severe mutation on the CYP21A2 next to the
TNXB gene, and the presence of a wild-type CYP21A2 next to the
TNXA pseudogene.
Two other gene duplications were found by Real-Time PCR in
two chromosomes bearing a chimeric CYP21A1P/CYP21A2. The
duplications had been suspected by the presence of heterozygosity
in the PCR products of a CYP21A2 fragment despite the fact that
both individuals were carriers of p.Ile236Asn, p.Val237Glu, and
p.Met239Lys mutations, which prevented the specific primer from
its binding. The PCRs for the specific amplification of each
CYP21A2 duplicated gene confirmed the duplication. The
sequencing of each gene showed the chimeric CYP21A1P/
CYP21A2 gene next to the TNXA pseudogene, and the presence
of a wild-type CYP21A2 next to the TNXB gene.
The total number of duplications found in our sample results in
a duplication allele frequency of 0.035, which meant a 7%
frequency of carriers. Most of them bore the p.Gln318X mutation
in one of the CYP21A2 genes.
Sequence Variations: frequency of putative disease-
causing alleles
A total of 22 CYP21A2 mutated alleles were found (Table 1),
which indicated that 16% of individuals were mutation carriers.
No significant differences were found between males and females.
Seventeen of these CYP21A2 genetic variants were known to
maintain a residual 21-hydroxylase enzyme (21OH) activity, 2
completely impaired it, and 3 were novel variants with an
unknown effect on the 21OH activity (Table 1).
Mild mutations. The allele frequency for mild mutations
was 0.059. The most frequent was p.Val281Leu, which was
carried by 11% individuals.
Severe mutations. The allele frequency for severe mutations
was 0.007. A chimeric CYP21A1P/CYP21A2 gene was carried by
an individual and p.Gly291Ser was carried by another.
Novel genetic variations. In our sample, 0.010 alleles
carried novel genetic variants: p.Trp22Cys, p.Asp184Asn, and
p.Thr443Asn. Each of these was found in different individuals
(Figure 2). The effect of these mutations on the 21OH activity is
unknown.
Figure 1. Organization of RCCX module and Copy Number Variations at chromosome 6p21. Black horizontal arrows denote gene
orientation. A. Specific primers used for the amplification of CYP21A2 next to TNXB. B. Specific primers used for the amplification of CYP21A2 next to
TNXA. Primer binding sites for each primer are indicated by grey horizontal arrows.
doi:10.1371/journal.pone.0002138.g001
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Table 1. CYP21A2 genetic variations found in a random sample of 144 Spaniards.
Type of Variation!! Genetic variation{ Sequence Variation at protein level£ 21OH& activity# Nu of alleles (allele frequency)
Mild c.844G.T p.Val281Leu 20–50% 16 (0.0555)
c.91C.T p.Pro30Leu 30–60% 1 (0.0035)
Severe Conversion * 0% 1 (0.0035)
c.874G.A p.Gly291Ser 0.8% 1 (0.0035)
Novel c.1996C.A p.Thr443Asn unknown 1 (0.0035)
c.553G.A p.Asp184Asn unknown 1 (0.0035)
c.69G.T p.Trp22Cys unknown 1 (0.0035)
Gene duplications c.[Conversion;Wt] p.[1;Wt] 100% 1 (0.0035)
c.[Conversion;Wt] p.[{;Wt] 100% 1 (0.0035)
c.[955C.T;Wt] p.[Gln318X;Wt] 100% 8 (0.0278)
!!Single Nucleotide Polymorphisms and the insertion of CTG encoding Leu10 are not reported in this table.
{GenBank Ref. ID NM_000500.5.
£UniProtKB ID P08686.
&21OH: 21-hydroxylase.






Figure 2. Electropherograms obtained for the three novel mutations in CYP21A2 gene and the corresponding wild-type alleles. 1.
The base change from G to T at position 69 leads to the substitution of tryptophan 22 by cysteine; 2. The base change from G to A at position 553
replaces aspartic acid 184 by asparagine; 3. The base change from C to A at positition 1996 leads to the substitution of threonine 443 by asparagine.
(GenBank Ref. ID NM_000500.5; UniProtKB ID P08686). Wt: wild-type; Mut: mutated.
doi:10.1371/journal.pone.0002138.g002
21OHD Genetic Variability
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CYP21A2 gene polymorphisms and haplotypes
In the 288 chromosomes analyzed, a total of 79 different genetic
variants were found. They were distributed in the vicinity 59 and
39 UTR of the CYP21A2 gene as well as in introns and exons.
Haplotype inference from data obtained for the 20 most
polymorphic genetic variations enabled the identification of 75
different haplotypes. Most of them appeared only once, but others
were recurrent. These latter were the haplotype associated to the
p.Gln318X mutation, which is unique, or the haplotype associated
to the p.Val281Leu mutation, which was present in 75% of these
mutated alleles (data not shown).
Discussion
The estimated frequency of 21OHD allele carriers among
different populations is 1.8% when inferred from the hormonal
neonatal screening data [1,28], which is designed to detect mostly
the classic form of 21OHD. The frequency determined by CYP21A2
genotyping, which also detects NC21OHD, is from 4% to 10%
[4,10]. It has been reported that 14% of classic forms and 84% of
non-classic forms are missed on the neonatal screening performed
during the first days of life [29]. There are no 21OHD carrier
frequency data for the Spanish population based on CYP21A2
genotyping. In this study, the complete analysis of the CYP21A2 gene
has been performed in 144 random volunteers. The object of the
study was firstly, to determine the frequency of 21OHD carriers and
secondly, to characterize rare RCCX modules in alleles with
duplicated CYP21A2. Although the sample size was small, our data
concord with previously published studies (8); it may have been
preferable to have determined the carrier frequency using a larger
sample; this, however, was both time-consuming and expensive.
Copy number variations (CNVs) have been described for the
RCCX locus: the presence of two RCCX modules is the standard
and the presence of one, three or even four modules are rare
arrangements. The trimodular organization accounts for only 14%
of the chromosomes in population studies [23] and the majority
carry two copies of the CYP21A1P pseudogene and one copy of the
CYP21A2 gene. The trimodular haplotype has also been described
with two copies of the CYP21A2 gene and one copy of the
CYP21A1P pseudogene. This latter haplotype has been described,
in some carriers of the p.Gln318X mutation and chimeric
CYP21A1P/CYP21A2 genes, as a rare event [23–27]. Our series,
however, have shown a high frequency of this arrangement, 7% of
individuals. The specific amplification and sequencing of each
duplicated gene localized the p.Gln318X mutation at the
CYP21A2 gene next to TNXB gene and it showed a wild-type
CYP21A2 at the 39UTR of TNXA pseudogene. Thus, PCR
approaches [30] based on the specific amplification of CYP21A2
like genes next to TNXB would fail in the detection of the wild-type
gene and would misdiagnose these duplicated alleles as pathologic,
which they are certainly not.
The duplicated CYP21A2 alleles found bear one inactivated
gene due to the severe mutations and a wild-type gene which
abolishes the pathological effect of the mutation. Furthermore,
CYP21A2 duplications have recently been reported as a risk factor
for de novo mutations in the offspring [13]. Hence, an awareness of
the presence of these types of gene duplications is important if a
misdiagnosis is to be avoided. A possible misdiagnosis could be the
erroneous identification of a wild type allele as pathological. This is
critical for the molecular diagnosis of 21OHD, as well as for
prenatal testing and for genetic counseling.
We found that 15.3% of individuals from our sample were
carriers of CYP21A2 mutations including novel variants. As far as
we know, this is the highest carrier frequency described so far.
The percentage of individuals who were carriers of NC21OHD
was 12%. The application of Hardy-Weinberg equilibrium to our
frequency data, estimated the incidence of the mild form of the
disease in 1:225. This value is a more precise estimation than the
incidence estimated by clinical diagnosis because the latter may
underdiagnose patients with mild phenotypes [2]. The frequency
of NC21OHD carrier found by genotyping in unselected Middle
Europeans and New Zealanders was lower than ours [4,10]. This
may reflect ethnic differences between the populations studied.
Although it should be noted that we sequenced the complete
CYP21A2 gene whereas the other genotyping based studies only
analyzed the 9–11 most common mutations.
In this investigation, as the Middle Europeans and New
Zealanders studies, the p.Val281Leu mutation was the most
common mutation among NC21OHD alleles (94% in our
sample). This was consistent with the reported mutational
spectrum of non-classic patients [2,18].
The frequency of carriers of severe mutations found (1.4%)
corresponded with the incidence of the classic form observed in
ours, as well as other populations. It is also similar to data obtained
from genotyping in New Zealanders [10,21]. Nevertheless, it is
much lower than the frequency described for Middle European
population (5.5%) [4]. This may reflect a different incidence of
classic 21OHD when European populations were compared [6–
8]. The frequency of CYP21A2 deletions and chimeric CYP21A1P/
CYP21A2 genes found was lower than the 15–20% described by
other authors [31,32]. However, it corresponded with our previous
work [18] and it is similar to the frequency observed in classic
21OHD patients from Italy, France or England [33–35].
Three novel genetic variants were found, (p.Trp22Cys,
p.Asp184Asn, and p.Thr443Asn) which account for approximate-
ly 1% of chromosomes. Two of them, p.Trp22Cys and
p.Thr443Asn, are predicted to damage 21-hydroxylase activity
(PolyPhen tool (http://genetics.bwh.harvard.edu/pph/)). The
high frequency of novel genetic variants shows the importance
of sequencing the whole CYP21A2 gene before it can be considered
as wild-type. In some cases, the effect of novel genetic variants may
be deduced from the phenotype of the patients. Nevertheless, in
vitro functional studies are needed to ascertain them and, if
possible, they should be made before considering a variation as a
pathological mutation or as a functional polymorphism.
The CYP21A2 analysis in our Spanish random population has
confirmed that this gene is one of the most polymorphic human ones,
as it has already been described by Cargill and co-workers [36]. We
found up to 79 different genetic variations at this locus. Twenty of
these genetic variations showed a minor allele frequency higher than
0.01. These polymorphic variations rendered up to 73 different
haplotypes (data not shown), most of them occurred only once.
In conclusion, as far as we know, the present study has shown
the highest frequency of 21OHD carriers reported by a
genotyping analysis. In addition, CYP21A2 gene duplications with
one of the copies mutated have been found to be a common event.
Moreover, a high frequency of novel genetic variants with an
unknown effect on 21OH activity was found and represents a
source of uncertainty in 21OHD genetic diagnosis. The number of
novel variants, as well as gene duplications found here, could be as
high in other populations and should be considered when the
21OHD genetic diagnosis and genetic counseling is carried out.
Materials and Methods
DNA samples
The CYP21A2 gene was studied in a random sample of 144
individuals (95 females, 49 males) recruited from the university
21OHD Genetic Variability
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students and employees of the hospital. Information about their
parents’ and grandparents’ geographic origins was provided. All
these individuals gave informed consent for the analysis, and the
procedures were conducted according to the principles expressed
in the Declaration of Helsinki.
Genetic analysis
DNA was extracted from peripheral blood leucocytes by
standard procedures.
Sequencing. The CYP21A2 gene and the closest 59 and 39
UTR were sequenced after being amplified in two overlapping
fragments by the polymerase chain reaction method as previously
described [18].
CYP21A2 copy number assessment:. For the CYP21A2
gene dosage assessment, 100 ng of DNA were used. The analytical
procedure was based on a Real-Time PCR method, using specific
primers for the amplification of the CYP21A2 gene, and TaqManH
(Applied Biosystems) probes as previously described [37].
Specific amplification of each duplicated CYP21A2
gene. Different DNAs previously characterized by southern
blot and the Real-Time PCR method were used as controls for the
following PCRs
A.- For the amplification of the CYP21A2 at the 39 UTR of
TNXB, the strategy described by Lee HH and co-workers was
followed [30]. This is based on the amplification of an 8515 bp
fragment by the use of a reverse primer (Tena32F), which anneals
specifically to exon 32 of TNXB. The forward primer (CYP779F) is
common for the 59 UTR of CYP21A2 and CYP21A1P. The
samples with a single copy of CYP21A2 on a chromosome, as well
as those samples with two copies of CYP21A2 on the same
chromosome, have to be positive for this PCR.
B.- For the amplification of the CYP21A2 gene at the 39 UTR of
TNXA, we designed three different PCRs using a forward primer
(P3S) that anneals specifically to exon 3 of CYP21A2 and: B1, a
reverse primer (1R), which anneals to TNXA producing a fragment
of 4611 bp. B2, with reverse primer (2R), which specifically
anneals to RP2 and forward primer (P3S) resulting in a 7042 bp
fragment and B3, with a reverse primer (3R), which anneals to C4
producing a 7475 bp fragment. (Figure 1) The samples with a
single copy CYP21A2 on a chromosome have to be negative for
these PCRs, while samples with two CYP21A2 copies on a
chromosome have to be positive for these PCRs. (Table S1. PCR
conditions under request).
The duplicated CYP21A2 alleles found were subjected to these
PCRs and the products obtained were sequenced in order to know
whether the p.Gln318X mutated copy and the chimeric
CYP21A1P/CYP21A2 genes were next to TNXB or to TNXA.
Haplotype construction. The Bayesian statistical method
implemented in the program PHASE v2.1.1 was used for the
haplotype construction. Only DNA variations, pathologic or not,
with a minor allele frequency higher than 0.01 were considered.
This selection criterion resulted in 20 genetic variations distributed
all over the CYP21A2 gene, as well as the closest 59 and 39 UTR.
Eighteen of these variations were biallelic markers, and two were
triallelic markers: rs6451 and rs6467. It was also included the
polymorphic insertion of an extra leucine in exon 1, and the
deletion of a G at position -106 of intron 2 (rs41315224).
Supporting Information
Table S1 Sequences of primers.
Found at: doi:10.1371/journal.pone.0002138.s001 (0.03 MB
DOC)
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